Skip to main content
MS-DRG 823 · MDC 17 · Surgical

MS-DRG 823: Lymphoma and Non-Acute Leukemia with Other Procedures with MCC

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: IPPS Table 5 FY2027 final rule (effective October 1, 2026); Definitions Manual v44 (effective October 1, 2026). Next CMS release: April 1, 2027 (v44.1 mid-year update), then the FY2028 final rule in August 2027.

Key facts for DRG 823

FY2027 relative weight
4.6050
Higher than 89% of all MS-DRGs
Change vs FY2026
+0.4%
FY2026 weight 4.5850
Geometric mean LOS
9.9 days
Arithmetic mean 13.2 days
MDC
17
Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
Severity level
with MCC (major complication or comorbidity)
Transfer policy
Not a transfer DRG

TL;DR

MS-DRG 823 is a surgical group in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms) at the highest-severity level of its family. CMS assigns it a FY2027 relative weight of 4.6050 with a geometric mean length of stay of 9.9 days and an arithmetic mean of 13.2. Its weight moved up 0.4% from FY2026 (4.5850). That weight is higher than 89% of all surgical and medical MS-DRGs. Its CC/MCC family (DRG 824, DRG 825) spans weights 1.2990 to 4.6050. The v44 Definitions Manual assigns it through 519 principal diagnosis codes.

What changed from FY2026 to FY2027

CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 823 the FY2027 relative weight is 4.6050 against 4.5850 in FY2026, a rise of 0.44%.

FY2026 versus FY2027 payment factors for MS-DRG 823
MetricFY2026FY2027Change
Relative weight4.58504.6050+0.0200
Geometric mean LOS (days)10.19.9-0.2
Arithmetic mean LOS (days)13.613.2-0.4
Weights shown are the FY2027 final values after the 10% cap on year-over-year reductions where applicable.

CC and MCC family

DRG 823 shares its base definition with 2 other MS-DRGs split by severity. The family's weights span 1.2990 to 4.6050, a 3.55× spread, which is the payment effect of documenting qualifying complications and comorbidities.

MS-DRGs in the same base group as DRG 823
DRGTitleFY2027 weightGMLOS
823Lymphoma and Non-Acute Leukemia with Other Procedures with MCC4.60509.9
824Lymphoma and Non-Acute Leukemia with Other Procedures with CC2.25104.9
825Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC1.29902.2

Grouper logic (v44 Definitions Manual)

Principal Diagnosis: 519 ICD-10 codes drive assignment to this group; the first 12 are shown.

Principal Diagnosis codes assigned to DRG 823 (sample)
ICD-10 codeDescription
C261Malignant neoplasm of spleen
C463Kaposi's sarcoma of lymph nodes
C770Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck
C771Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes
C772Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
C773Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes
C774Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes
C775Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes
C778Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions
C779Secondary and unspecified malignant neoplasm of lymph node, unspecified
C7B01Secondary carcinoid tumors of distant lymph nodes
C8100Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site

Documentation and denial exposure

As a surgical DRG, assignment depends on a qualifying operating-room procedure being coded from the operative report; a missing or non-OR procedure code drops the stay into a medical DRG in MDC 17 with a lower weight. Because this family splits by severity, auditors target CC and MCC capture: each secondary diagnosis must be documented as present, monitored, evaluated or treated during the stay to survive a DRG-validation review. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).

How QuickIntell uses DRG 823 data

QuickCode groups inpatient encounters against the current v44 logic, flags CC and MCC candidates that lack supporting documentation, and shows the weight difference across the family before the claim drops. QuickScribe captures the attending's language that supports severity, and QuickRCM works DRG-validation denials with the grouper evidence attached.

Frequently asked questions — DRG 823

What is MS-DRG 823?

MS-DRG 823 is "Lymphoma and Non-Acute Leukemia with Other Procedures with MCC", a surgical Medicare Severity Diagnosis-Related Group in MDC 17, Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms. Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.

What is the FY2027 relative weight for DRG 823?

The FY2027 relative weight is 4.6050 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 4.5850, a change of +0.4%.

What is the average length of stay for DRG 823?

CMS reports a geometric mean length of stay of 9.9 days and an arithmetic mean of 13.2 days for FY2027. The geometric mean is used for transfer-payment calculations.

Which DRGs are in the same CC/MCC family as 823?

DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, weight 2.2510); DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, weight 1.2990). The family's weights range from 1.2990 to 4.6050, so documented complications and comorbidities change payment materially.

What documentation supports the severity level of DRG 823?

DRG 823 requires at least one secondary diagnosis on the CMS Major Complication or Comorbidity list, documented as present and clinically addressed during the stay (monitored, evaluated, treated or extending the stay). Conditions such as acute respiratory failure, severe sepsis or acute kidney injury with specified cause qualify only when the attending's note states the diagnosis itself, not just the lab values. Recovery auditors downgrade this group to the CC or base level when the MCC rests on an unconfirmed query or a resolved historical condition, so the query response and the discharge summary must agree.

Which codes group to DRG 823?

The v44 Definitions Manual lists 519 principal diagnosis codes for this group. Examples from the principal diagnosis list: C261 (Malignant neoplasm of spleen); C463 (Kaposi's sarcoma of lymph nodes); C770 (Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck); C771 (Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes).

Is DRG 823 a post-acute transfer DRG?

No. DRG 823 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-01. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.